The autumn season officially starts today and the business world along with the Bullboards have certainly picked up in activity.

Every week we track the most-viewed Bullboards in each sector and bring you some of the highlights. Some companies caught the eye of investors, while others found themselves catching ire.

This week we look at three companies that have earned spots on the charts. One is a well-known business in non-tobacco based, smokable products, the other is a technology favourite at Stockhouse, but the first on our list is a busy company in the energy Bullboards.

We are living in an unprecedented energy crunch, but one public company has continued to advance its operations.

Trillion Energy International (CSE:TCFForum) has begun its multi-well drilling program on the SASB natural gas field in the Black Sea.

The Uranus Rig was mobilized to the Akçakoca platform where the first wells are being drilled following maintenance and weather delays.

The company will drill three directional wells from Akçakoca, plus one recompletion of an existing well, over an estimated six-month timeframe.

First gas production is planned for early November 2022, with sales soon to follow, at a time of acute fuel shortages in Europe and Turkey. Trillion will receive monthly revenue (US$31/mcf) under its existing gas contract to fund further drilling.

After finalizing its work at Akçakoca, the rig will move to the next of SASB’s three platforms to continue the work program.

Heated tobacco product sales have jumped in Europe of late. TAAT Lifestyle & Wellness Ltd. (CSE: TAATForum) dispatched a “full-container” shipment to the United Kingdom this week, marking the company’s largest U.K. shipment to date.

This shipment will be used to further expand the distribution of TAAT into additional markets in the southeastern region of the United Kingdom, which the company is presently coordinating with Green Global Earth (GGE), its U.K. wholesale partner.

TAAT is mainly sold in South London; a presence that the company and GGE intend to expand organically into new markets in nearby regions.

From uncovering the cellular origins of Alzheimer’s disease, to supporting first aid at Oktoberfest, artificial intelligence (AI) is seemingly capable of helping humans in a variety of ways. Companies like Datametrex AI Ltd. (TSXV:DMForum) are also finding ways of making it better.

Its subsidiary, Nexalogy, is continuing work on the second phase of a $40 million Canadian AI project.

The project was first announced in January. The first phase of this contract has been completed.

The contract is on track for the scheduled completion in March 2023.

Datametrex has been tasked to collaborate with its partner using Nexalogy’s Social Media Automated Reporting Technologies (SMART) to speed up time to investigate social media influencer activities.

SMART reduces the time needed to interpret and integrate large sets of data by offering powerful automated analyses. SMART extracts the relevant data and produces automated reports, thus allowing clients to work with a more manageable information set. SMART allows an analyst to deal with hundreds of thousands of social media documents in minutes rather than hours or days.

Next week on Buzz on the Bullboards we’ll round out the month of September and see how sectors are shaping up during the autumn season.

Get “Buzz on the Bullboards” delivered to your inbox every Thursday. Sign Up Here


More From The Market Herald

" @ the Bell: TSX snaps six-day selloff

A day after posting its longest streak of daily declines since May, Canada’s main stock index rose on Wednesday led by precious metal

" Silvercorp Metals Inc. Confirms Its Golden Potential with a Reserve and Resource Update

By Dr. Ryan D. Long

" No pain, no blood: BETTER Type 2 diabetes testing is coming to market

Over the past two years, reporting on the Covid-19 pandemic has dominated media airwaves.
The Market Herald Video

" BioVaxys (CSE:BIOV) expands vaccines intellectual property portfolio

BioVaxys Technology Corp. (BIOV) has broadened patent coverage for its viral vaccine platform.